Magtein: Rage Ƙaruwa na Dawa Opioid a Majinyatan Ciwon Daɗi? Abinda Binciken Ya Gano

Gabatarwa

Magnesium‑L‑threonate (L‑TAMS), da ake sayarwa a kasuwa da sunan Magtein, an san shi da ƙara lafiyar kwakwalwa da inganta barci. An yi wani gwaji kan majinyata da ke fama da ciwon daɗi na mataki na ƙarshe, waɗanda ke shan opioid a baki, domin tantance ko ƙara Magtein na iya rage yawan opioid da suke bukata. A cikin majinyata 83, an ga cewa adadin morphine da suke sha a kowace rana ya ragu kusan rabi idan aka kwatanta da waɗanda suka samu placebo a tsawon kwanaki 90. Haka kuma, an lura da raguwar kumburin ciki – ɗaya daga cikin mummunan sakamakon opioid. Duk da haka, wannan gwaji ƙanana ne, an gudanar da shi a asibiti guda a China, kuma ba ya nufin a canza magani ba tare da shawarar likita ba.

Babban Sakamako: Rage Ƙaruwa na Dawa

Takardar da aka wallafa a Cancer Medicine (2023) ta binciki tasirin magnesium‑L‑threonate, wadda ake kira L‑TAMS. Wannan ƙarin magnesiyam na da alama a kasuwa da Sunan Magtein, kuma ana kira shi “nootropic” saboda kallon hana lalacewar kwakwalwa. Gwajin bai auna matakin magnesiyam a cikin kwakwalwa ba, don haka duk wani tunani game da hakan ya samo asali ne daga bincike na baya.

Manufar binciken ita ce gano ko ƙara L‑TAMS a cikin maganin opioid zai rage yawan opioid da marasa lafiya ke buƙata. An auna ƙaruwa a kullum na adadin morphine da aka sha a baki – ma’anar da ke nuna yadda marasa lafiya ke ƙara buƙatar opioid don rike radadi.

Adadin morphine da aka sha a kowace rana

• Rana 30: 9.85 mg (L‑TAMS) vs. 20.49 mg (placebo), p < 0.05
• Rana 60: 15.96 mg vs. 29.06 mg, p < 0.05
• Rana 90: 21.20 mg vs. 40.44 mg, p < 0.01

A ranar 90, adadin morphine a rukuni na placebo ya ninka kusan sau biyu na na L‑TAMS. Rukuni biyu sun fara bambanta a ranar 30, yayin da ba a sami bambanci a ranaku 7, 14, da 21 ba.

Ƙari: Rage Kumburin Ciki

Masu bincike sun kuma lura cewa L‑TAMS yana rage kumburin ciki da opioid ke haifarwa – ɗaya daga cikin mafiya munin sakamakon opioid, wanda kan iyakance yawan maganin da marar lafiya zai iya ɗauka. Magnesiyam sananne ne a cikin magungunan laxative, don haka sakamakon ya dace da abin da ake tsammani. Takardar ba ta ba da ƙididdigar wannan raguwar ba, don haka ba a san girman ribar ba.

Yadda Aka Gudanar da Binciken

• Tsari: Gwaji mai rarrabuwa, double‑blind, placebo‑controlled.
• Wuri: Asibiti guda a Shanghai, China.
• Masu halarta: An yanka masu ciwon daɗi 116, aka zaɓi 83 da ke sha opioid a baki.
• Hanyar: Kapsul L‑TAMS (1.5 g ko 2.0 g bisa nauyin jiki) ko placebo (starch).
• Bibiya: An auna adadin morphine a ranaku 7, 14, 21, 30, 60, da 90.
• Rikicin sha'awa: Ba a ba da bayanin cikakken adadin lalacewa ba.

Tsarin double‑blind da placebo‑controlled shine mafi karfi don irin wannan tambaya, kuma yana ƙara amincewa da sakamakon.

Abubuwan Da Za Su Iya Amfani

Kayan da aka yi amfani da su: Gwajin ya yi amfani da 1.5 g ko 2.0 g na kapsul L‑TAMS, da aka daidaita da nauyin marasa lafiya. Takardar ba ta fayyace bambancin tsakanin waɗannan ƙima ba, kuma ba a bayyana ko adadin ya nuna ƙimar elemental magnesium ba – don haka kada a ɗauka cewa waɗannan ƙimomin sun dace da alamar kasuwa.

Lokaci: Ba a bayyana ainihin lokacin da marasa lafiya suka fara ɗaukar kapsul ba. Tasirin ya fara bayyana bayan kusan wata ɗaya, kuma ya ci gaba har zuwa watanni uku, alamar cewa tasirin na dogon lokaci ne, ba magani mai saurin aiki ba.

Wanene zai iya amfana: Majinyata manya masu ciwon daɗi a mataki na ƙarshe da ke shan opioid a bakin su a ƙarƙashin kulawar likita, kuma waɗanda ke fuskantar ƙaruwa da kumburin ciki. Wannan shine rukuni da binciken ya yi nazari a kansa. Ya kamata a tattauna da oncologist ko ƙwararren likitan ciwon daɗi kafin a yi amfani da shi.

Waɗanda ya kamata su guje shi ko aƙalla su tuntuɓi likita:

• Duk wanda ke tunanin amfani da Magtein a matsayin maye gurbin maganin da aka rubuta. Binciken ya gwada shi a matsayin ƙari.
• Mutane da ke son rage ko daina opioid ba tare da jagorancin likita ba – canza ƙudurin opioid ba tare da kulawa ba na iya zama haɗari.
• Mutane da ke da matsalar koda ko kuma suna shan magungunan da ke hulɗa da magnesiyam – wannan gargadi ne ga kowane ƙarin magnesiyam, ba takamaiman ga Magtein ba.
• Mutane ba masu ciwon daɗi ba. Masu lafiya da waɗanda ke da wasu yanayi ba a gwada su ba.

Ƙuntatawa Da Ya Kamata Ku San

1. Karamin misali. Majinyata 83 ne kawai, don haka sakamakon na buƙatar tabbaci a manyan rukuni.
2. Wurin guda. Dukkan marasa lafiya sun fito ne daga asibiti guda a China, wanda ke iyakance yaduwar sakamakon.
3. Ma’anar ƙaruwa. Ƙaruwa a cikin adadin opioid na nufin ƙara buƙatar magani don rike radadi, ba lallai ya nufin jin radadi ya ƙaru ba. Kammalawar takardar cewa L‑TAMS “yana ƙara ingancin maganin radadi” ya dogara ne kawai kan wannan ma’ana.
4. Bayanan da ba su bayyana ba. Muhimman bayanai kamar yawan ficewa, maki na radadi, da sauran sakamako ba su ƙunshi a takardar ba, don haka ba za a iya yin cikakken sharhi ba.
5. Babu tabbacin hanyar aiki. Ba a nuna ko magnesiyam yana aiki a kwakwalwa ko a spinal cord don ƙara tasirin opioid ba.

Kammalawa

Wannan gwajin rarrabe ya nuna cewa magnesium‑L‑threonate (Magtein) na iya rage saurin ƙaruwa a ƙudurin opioid da kuma rage kumburin ciki a cikin manyan majinyata masu ciwon daɗi. Duk da haka, sakamakon na farko ne, ba tabbataccen dokoki ba. Kowanne mai fama da ciwon daɗi ko mai kula da shi da ke sha'awar wannan ƙari ya kamata ya tattauna da ƙungiyar likita da ke kula da su, ta yadda za a tantance dacewarsa tare da la’akari da cikakken tarihi da yanayin lafiyar marar lafiya. Ba a ba da izinin canza maganin opioid da kansu ba.